Tag: Europe
-
EU-Funded Project to Develop Biomaterials for Stents
Ceram, a materials technology company in Stoke-on-Trent in the U.K., is coordinating a project funded by the European Commission to develop new biocompatible materials suitable for stents that help keep blood vessels open in the heart. The project, known as Rebiostent, is receiving €4.58 million of its €5.87 million ($US 6.19 million of $7.93 million)…
-
European Venture Licenses Biotech Drought-Resistant Traits
Genective, a joint venture between German and French seed companies to develop new corn varieties, is licensing engineered gene science from the biotechnology company Arcadia Biosciences Inc. in Davis, California. Arcadia Biosciences will receive initial, milestone, and sales royalty payments under the agreement, but the dollar amount of the deal was not disclosed. Arcadia Biosciences…
-
Trial Shows Gene Therapy Helps Treat Genetic Eye Disease
Researchers at University of Oxford in the U.K. report initial results of a clinical trial showing healthy genes injected into the retinas of patients with a rare inherited disease improved their vision after six months. Findings from the study led by Oxford eye surgeon Robert MacLaren are published in today’s online issue of the journal…
-
DNA Diagnostics Company to Crowdfund Malaria Testing Device
QuantuMDx, a biotechnology company in Newcastle, U.K. says it will start a crowdfunding campaign next month to finance development and field trials of a handheld device to test for malaria. The device is an application of its Q-POC point-of-care diagnostics system, which will be the subject of an Indiegogo campaign beginning 12 February. The company,…
-
Heart Vessel Surgical Glue Shown Effective in Animal Tests
Surgeons and biomedical engineers at Boston Children’s and Brigham and Women’s hospitals and Massachusetts Institute of Technology, developed a non-toxic, biocompatible surgical glue that in tests with pigs patches heart defects, such as those in large blood vessels. The team led by Boston Children’s Pedro del Nido and Jeffrey Karp of Brigham and Women’s Hospital…
-
MedImmune, Biotech to Partner on Cancer Immunotherapies
MedImmune in Gaithersburg, Maryland, the biologics division of pharmaceutical company AstraZeneca, and Immunocore Ltd. in Oxford, U.K. will develop cancer treatments that harness the body’s immune system, based on Immunocore’s technology. The deal will pay Immunocore, for each therapy program licensed by MedImmune, $20 million initially and another $300 million in milestone payments, as well…
-
Diabetes App Developer Files for FDA Pre-Market Clearance
LabStyle Innovations Corp. in Caesarea, Israel, developer of a mobile and cloud-based system for diabetes management, filed for pre-market notification of its system with the U.S. Food and Drug Administration. Pre-market notification, once granted by FDA, clears medical devices for marketing in the U.S. LabStyle Innovations created the Dario system that combines a small glucose…
-
U.S., Europe Pharma Industries Implement Trial Data Sharing
Pharmaceutical industry associations in the U.S. and Europe began implementing their agreement from this past summer to provide more access to data from clinical trials conducted by their member companies. One of those companies, Paris-based Sanofi, released its procedures today for accessing its clinical trial data. The new processes are a result of a set…
-
Large Genomic Study Finds New Rheumatoid Arthritis Targets
An international consortium of 70 institutions and companies combined genome-wide analyses with current drug databases to uncover new genomic targets for rheumatoid arthritis, and identify drugs for other diseases with the potential to treat the disorder. The team led by Robert Plenge of Harvard Medical School and the Broad Institute and Yukinori Okada from the…
-
FDA Approves Rare Congenital Blood Disease Treatment
The U.S. Food and Drug Administration yesterday approved a treatment for congenital factor XIII A-subunit deficiency, a rare blood clotting disorder, made by the pharmaceutical company Novo Nordisk, based in Denmark. Tretten, the medication’s brand name, is an engineered biologic designed to prevent bleeding in adults and children with the disorder. People with factor XIII…